ArticleHeadache
Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH study.
Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo compare the 3-month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
backgroundMultiple TOMP medications (within classes of beta-blockers, anticonvulsants, tricyclic antidepressants, angiotensin II receptor antagonists, and calcium channel blockers) originally developed to treat other conditions are used for migraine prevention. In a recent real-world analysis comparing galcanezumab with a broader classification of TOMP, a significantly greater proportion of patients treated with galcanezumab achieved a clinically meaningful response at 3 months (reduction from baseline in monthly migraine headache days) (46.6% vs. 34.5%, p < 0.001). Treatment selection is often individualized based on patients' historical and current clinical profiles, preferences, and comorbid conditions. Comparing the real-world effectiveness of galcanezumab with specific TOMP using stringent criteria based on established efficacy at a global level will provide additional insights.
methodsThe TRIUMPH (preventive TReatment of mIgraine: oUtcoMes for Patients in real-world Healthcare systems) study is an ongoing, international, prospective observational cohort study comparing the effectiveness of galcanezumab with other preventives (EUPAS33068). A priori sample size was achieved, and interim data (Feb 25, 2020, to Feb 9, 2023) were analyzed. The current analysis compared patients with migraine initiating galcanezumab versus the TOMP efficacy subset (drugs with established/probable efficacy based on the 2021 American Headache Society consensus statement incorporating the American Academy of Neurology classification of evidence and consistent with the European Headache Federation/European Academy of Neurology and Japanese Society of Neurology/Japanese Headache Society). Galcanezumab was also compared with the most frequently used individual TOMP drugs in the TRIUMPH study. Reduction in monthly migraine headache days (≥50%: episodic migraine, ≥30%: chronic migraine) from baseline to 3 months was assessed after adjusting for baseline cohort differences.
resultsAt the time of this analysis, 2398 patients from the United States, Japan, Germany, Italy, the United Kingdom, Spain, and the United Arab Emirates had completed baseline assessments. Topiramate (n = 343) and amitriptyline (n = 240) were the most frequently used TOMP drugs. At 3 months, the galcanezumab cohort (n = 1065) had a greater weighted proportion of responders versus the TOMP efficacy subset (n = 916) (48.3% [95% confidence interval [CI]: 45.1%, 51.6%] vs. 35.9% [95% CI: 32.6%, 39.3%]; p < 0.001), topiramate (n = 343) (48.8% [95% CI: 45.7%, 51.9%] vs. 37.2% [95% CI: 31.2%, 43.7%]), and amitriptyline (n = 240) (49.7% [95% CI: 46.6%, 52.8%] vs. 23.3% [95% CI: 17.5%, 30.4%]) cohorts.
conclusionIn this real-world study, galcanezumab induced a clinically meaningful reduction in migraine headache days in a higher proportion of patients than TOMP medications classified as efficacious, including topiramate and amitriptyline. TRIAL REGISTRATION NUMBER: EUPAS33068.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.